In a bold move, Vaccinex has forged eight new antibody discovery agreements with leading pharmaceutical and biotechnology companies, as well as str...
"This new partnership builds on our innovation strategy and will allow us to explore the innovative approach of IL-21 blockage as a possible new pa...
ProNephro AKI (NGAL) stands out as the first AKI biomarker test to secure FDA clearance for pediatric use, covering children from...
ChatGPT CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 16, 2024 07:00 AM Eastern Standard Time Sarepta Therapeutics, Inc. (NASDAQ:...
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announ...
Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced tha...
Johannesburg is now the hub for all Southern African countries. In addition to SouthAfrica; Botswana, Namibia, Mozambique, Zambia, Zimbabwe, Lesotho, Ang...
Designed for versatility and ease of use, the Dionex Inuvion IC system offers comprehensive capabilities for the determination of ionic and small polar com...
Vetter, a globally recognized contract development and manufacturing organization (CDMO), proudly announces the successful market introduction of eight cus...
Exscientia plc (Nasdaq: EXAI), a frontrunner in AI-driven precision medicine, has officially announced a significant leadership adjustment and the submissi...
In an interview with BioPharma BoardRoom, Eric Blair, GDMC’s Chief Business Officer, discusses the company's strategic use of Series A funding to pio...
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion...
Viz.ai, a pioneering force in AI-driven disease detection and intelligent care coordination, has attained a significant milestone with the receipt ...
Takeda unveiled promising topline results from a comprehensive Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patien...
© 2025 Biopharma Boardroom. All Rights Reserved.
